Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

22results about How to "Reduce lesions" patented technology

Application of methylenetetrahydrofolate dehydrogenase 2 and coding gene thereof in vascular remodeling

The invention discloses application of methylenetetrahydrofolate dehydrogenase 2 and a coding gene thereof in vascular remodeling. The invention provides a new thought for preventing, treating and / or relieving vascular remodeling and / or vascular remodeling related diseases.
Owner:THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV

Endoscope system based on harmonic imaging and multiphoton fluorescence imaging

The invention discloses an endoscope system based on harmonic imaging and multiphoton fluorescence imaging. The endoscope system comprises a first femtosecond pulse laser, a second femtosecond pulse laser, a prism, an X-Y scanning galvanometer, a first long-wave-pass dichroscope, a coupling objective lens, an optical fiber bundle, an endoscope and an imaging device. The first femtosecond pulse laser and the second femtosecond pulse laser respectively emit near-infrared femtosecond pulse laser, the near-infrared femtosecond pulse laser enters the X-Y scanning galvanometer after being converged by the prism, then penetrates through the first long-wave-pass dichroscope, is coupled into the optical fiber bundle through the coupling objective lens, and finally is focused on a measured tissue through the endoscope. The first long-wave-pass dichroscope excites the detected tissue and the fluorescent substance thereof to generate second harmonic, third harmonic, two-photon fluorescence and three-photon fluorescence, and harmonic and fluorescence signals return along the same path and enter the imaging device after being reflected by the first long-wave-pass dichroscope, so that a second harmonic image, a third harmonic image, a two-photon fluorescence image and a three-photon fluorescence image of the detected tissue are obtained. Harmonic waves and multi-photon fluorescence imaging are combined, and pathological tissues in the cavity can be detected.
Owner:JOYMEDICARE (SHANGHAI) MEDICAL ELECTRONIC TECH CO LTD

Bacillus licheniformis and application thereof

ActiveCN119144510Aimprove researchreduce lesionsAntibacterial agentsBacteriaBiotechnologyBacillus licheniformis
The invention discloses a bacillus licheniformis strain and application thereof. Belongs to the technical field of probiotics. A strain of bacillus licheniformis is separated and identified through a traditional identification method and a molecular biological method, and the bacillus licheniformis is subjected to probiotic performance evaluation and animal in-vivo safety evaluation. Meanwhile, microbiology is combined with pathology and the like, so that mouse organ lesions caused by salmonella can be relieved by drenching the bacterium, and an antagonistic effect on salmonella in a mouse body can be generated. According to the invention, not only can the research on bacillus be expanded, but also a reference basis can be provided for developing and researching probiotic microecological preparations for promoting digestion and growth of animals, antagonizing pathogenic bacteria, regulating intestinal microecological environment and the like in the future.
Owner:INNER MONGOLIA AGRICULTURAL UNIVERSITY

Kudzuvine root and sesame coffee for improving non-alcoholic fatty liver and application of kudzuvine root and sesame coffee

The invention relates to the technical field of biological medicine, in particular to radix puerariae and sesame coffee for improving non-alcoholic fatty liver and application of the radix puerariae and sesame coffee. The radix puerariae and sesame coffee comprises the following components in parts by weight: 0.5 part of a fructus cannabis polypeptide solution, 0.5 part of radix puerariae polypeptide solution and 9 parts of coffee. After continuous treatment for 7 weeks, according to liver appearance and liver histopathology observation, it is found that the radix puerariae and sesame coffee mixed liquid effectively reduces lipid deposition and liver fat, and the liver fat lesion is improved. Experimental results show that the radix puerariae and hemp coffee has a remarkable lipid-lowering effect, and can effectively reduce liver fat particles, reduce inflammatory injury, improve liver tissue pathological changes and relieve NAFLD mouse liver tissue injury.
Owner:YUNNAN UNIVERSITY OF CHINESE MEDICINE +1

Application of elastase inhibitor in preparation of medicine for treating cerebral perfusion insufficiency

The invention relates to the field of medicine, in particular to application of an elastase inhibitor in preparation of a medicine for treating cerebral perfusion insufficiency. Research finds that the expression quantity of NE in the corpus callosum of a patient suffering from cerebral perfusion insufficiency is increased, NE can cause brain oligodendrocyte damage and white matter lesion, and the elastase inhibitor can effectively inhibit the expression quantity and activity of NE, relieve oligodendrocyte damage and relieve the enzyme digestion effect of NE on myelin CNPase at the same time, so that the corpus callosum in the patient suffering from cerebral perfusion insufficiency can be effectively inhibited, and the corpus callosum in the patient suffering from cerebral perfusion insufficiency can be effectively inhibited. The myelin sheath injury of the corpus callosum region is reduced, so that white matter lesion is inhibited.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Bacterial strain, composition, drug for use in combination, and use

PendingEP4349350A4avoid rapid accumulationavoid functional damage
Provided are Christensenellaceae, and a composition and a pharmaceutical use thereof. The Christensenellaceae can be used for treating or preventing liver function damage and related diseases, digestive tract mucosa damage and related diseases, diabetes, obesity, and related diseases. The Christensenellaceae can also be used in combination with hypoglycemic and lipid-lowering drugs, and has a synergistic effect on liver function damage and related diseases, diabetes, and obesity and related diseases.
Owner:MOON (GUANGZHOU) BIOTECH CO LTD

A kind of inulin fermentation product for reducing blood sugar and its preparation and application

The present invention provides a blood sugar lowering inulin fermentation product and its preparation and application, belonging to the field of microbial fermentation technology. The blood sugar lowering inulin fermentation product is obtained by fermenting inulin with a specific fermentation bacterium, Schleiferilactobacillus harbinensis JNDM, which has been deposited in the Guangdong Provincial Microbiological Culture Collection Center on December 11, 2023, with a deposit number of GDMCC No. 64143. The inulin fermentation product can significantly enhance the blood sugar lowering effect of inulin, reduce complications of hyperglycemia, improve anti-inflammatory function, and effectively relieve pancreatic and renal tissue lesions; it can regulate the homeostasis of intestinal flora, and significantly increase the diversity of intestinal microorganisms and the content of beneficial metabolites in the intestine. It can be used as a food, health product, medicine or functional beverage for preventing and treating type 2 diabetes and its complications or for lowering blood sugar.
Owner:CHANGZHOU WANHE BIOTECHNOLOGY CO LTD

Esophageal cancer resisting medicine derived from fresh rabdosia rubescens and preparation method of esophageal cancer resisting medicine

The invention provides an anti-esophageal cancer medicine derived from fresh rabdosia rubescens and a preparation method of the anti-esophageal cancer medicine, and relates to the technical field of pharmacy of fresh traditional Chinese medicines. According to the invention, fresh rabdosia rubescens is taken as a basic medicinal material, an extraction process is improved and optimized, an extract containing Oridonin (Ori) and rosmarinic acid (RA) is obtained, and the esophageal cancer resisting effect of the fresh rabdosia rubescens extract is researched. Experimental results show that the treatment effect of Ori combined with RA administration on esophageal cancer model mice is remarkable, the effect is better than that of Ori or RA independent administration, and it is shown that oridonin and rosmarinic acid are combined for use, and the esophageal cancer resisting effect can be remarkably improved. The invention provides a novel medicine and a novel treatment thought for treating esophageal cancer.
Owner:HENAN UNIV OF CHINESE MEDICINE

A COMBINATION OF ANTI-PD-1 ANTIBODIES AND RADIATION TO TREAT CANCER

ActiveMA44978AImprove anti-tumor efficacyreduce lesions
Owner:REGENERON PHARMACEUTICALS INC

Morchella esculenta polysaccharide and application of degraded Morchella esculenta polysaccharide in prevention and treatment of ulcerative colitis

The invention discloses morchella polysaccharide and application of degraded morchella polysaccharide in prevention and treatment of ulcerative colitis. The degraded morchella esculenta polysaccharide is obtained by degrading the morchella esculenta polysaccharide by adopting an ultrasonic combined H2O2-VC method. The morchella esculenta polysaccharide or degraded morchella esculenta polysaccharide slows down weight loss and colon length shortening of a patient, improves colon pathological conditions, reduces the oxidative stress level of the patient, reduces the MDA content in colon tissue of the patient, enhances the vitality of CAT, SOD and GSH, and can be used for preventing and treating the disease of the patient. According to the present invention, with the application of the traditional Chinese medicine composition, the secretion level and the gene expression level of IL-1beta, IL-6 and TNF-alpha can be reduced, the secretion level and the gene expression level of IL-10 can be improved, the damage of intestinal barrier cells caused by DSS can be repaired, the number of goblet cells can be increased, the infiltration of inflammatory cells can be reduced, the richness of intestinal flora can be improved, the dominant bacteria can be increased, the harmful bacteria can be reduced, and the recovery of intestinal flora can be promoted; the invention provides a novel medicine for preventing and treating ulcerative colitis.
Owner:SHANXI AGRI UNIV

A strain of Enterococcus monteri and its application

ActiveCN119040228Breduce lesionsimprove researchAntibacterial agentsBacteriaAntagonismGenus Enterococcus
The present invention discloses a strain of Enterococcus mundtii and its application. It belongs to the technical field of probiotics. A strain of Enterococcus mundtii is separated and identified by traditional identification methods and molecular biological methods, and its probiotic performance and in vivo safety evaluation are performed. At the same time, microbiology is combined with pathology, etc., and it is found that oral administration of the bacteria can reduce organ lesions in mice caused by Salmonella, and can produce antagonistic effects on Salmonella in mice. The present invention can not only expand the research on the genus Enterococcus, but also provide a reference basis for the future development of probiotic microecological preparations for promoting digestion and growth in animals, antagonizing pathogens, and regulating intestinal microecological environments.
Owner:INNER MONGOLIA AGRICULTURAL UNIVERSITY

Snakegourd fruit alkaloid extract as well as extraction method and application thereof

The invention relates to a trichosanthes kirilowii maxim alkaloid extract and an extraction method and application thereof, and belongs to the technical field of trichosanthes kirilowii maxim extract preparation. The extraction method comprises the following steps: performing ultrasonic extraction on trichosanthes peel powder for multiple times by using a sulfuric acid solution, combining extracting solutions obtained by multiple times of extraction, performing primary concentration on the combined extracting solutions, then adjusting the pH value of the extracting solutions obtained by primary concentration to a target pH value, performing extraction for multiple times by using n-butyl alcohol, combining the extracting solutions obtained by multiple times of extraction, performing secondary concentration to obtain paste, and performing spray drying to obtain the trichosanthes peel extract. The trichosanthes kirilowii maxim alkaloid extract is obtained. The content of alkaloid in the trichosanthes kirilowii maxim alkaloid extract is 60-70%, and the trichosanthes kirilowii maxim alkaloid extract contains 20 kinds of alkaloid, has a good anti-atherosclerosis pharmacological action, and can remarkably improve liver lipid deposition, liver lipid metabolism disorder and abnormal blood lipid level of atherosclerosis mice.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE

Application of ISG15-(H4)2-IFN-λ3 recombinant protein in the preparation of drugs for preventing and treating PRRSV infection

ActiveCN119139459BImprove biological activitystable expressionInflammatory factorsISG15
The present invention belongs to the field of biotechnology, and specifically relates to the application of ISG15-(H4)2-IFN-λ3 recombinant protein in the preparation of drugs for preventing and treating PRRSV infection. The present invention selects (H4)2 connecting peptide to connect ISG15 and IFN-λ3 to prepare ISG15-(H4)2-IFN-λ3 recombinant protein, which can achieve stable and large-scale expression of IFN-λ3 protein, solves the technical problem that IFN-λ3 cannot be mass-produced using a prokaryotic expression system, and at the same time, the present invention verifies the anti-PRRSV activity of ISG15-(H4)2-IFN-λ3 recombinant protein in vivo, proving that the recombinantly expressed ISG15-(H4)2-IFN-λ3 recombinant protein has an inhibitory effect on inhibiting the replication of PRRSV in vivo, reduces the secretion of inflammatory factors in the lungs and improves the viremia caused by PRRSV infection.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Application of ISG15-(H4) 2-IFN-lambda3 recombinant protein in preparation of medicine for preventing and treating PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) infection

The invention belongs to the technical field of biology, and particularly relates to an application of ISG15-(H4) 2-IFN-lambda3 recombinant protein in preparation of a medicine for preventing and treating PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) infection. According to the present invention, the (H4) 2 connecting peptide is selected to connect the ISG15 and the IFN-lambda3 to prepare the ISG15-(H4) 2-IFN-lambda3 recombinant protein, such that the stable and mass expression of the IFN-lambda3 protein can be achieved, the technical problem that the mass production of the IFN-lambda3 cannot be achieved by using the prokaryotic expression system is solved, the in-vivo PRRSV resistance activity of the ISG15-(H4) 2-IFN-lambda3 recombinant protein is verified, and the in-vivo PRRSV resistance activity of the ISG15-(H4) 2-IFN-lambda3 recombinant protein can be provided for the prokaryotic expression system. It is proved that the recombinant expression ISG15-(H4) 2-IFN-lambda3 recombinant protein has an inhibition effect on inhibition of PRRSV replication in vivo, reduces secretion of inflammatory factors in lungs and improves viremia caused by PRRSV infection.
Owner:SHENZHEN RESEARCH INSTITUTE OF NORTHWEST A & F UNIVERSITY

Use of gbp4 gene silencing preparation in preparation of drugs for preventing and treating atherosclerosis

PendingCN122499326Areduce lesionsreduce area
The present application relates to the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and belongs to the technical field of biological medicine. In order to solve the technical problems that the existing atherosclerosis treatment target is single, cannot target regulate chronic inflammation of blood vessels, and is difficult to suppress disease progression from the root, the present application provides the application of GBP4 gene silencing preparation in the preparation of drugs for preventing and treating atherosclerosis, and the gene silencing preparation is a recombinant lentivirus vector carrying shRNA targeting GBP4. The present application first finds that GBP4 is a positive regulator of atherosclerosis, and the GBP4 gene silencing preparation can reduce the area of atherosclerotic plaque, delay the occurrence and development of atherosclerosis; increase the thickness of the fibrous cap of the plaque, enhance the stability of the plaque, and reduce the risk of plaque rupture; at the same time, reduce the systemic inflammation level, reduce the inflammatory response of the blood vessel wall, and have important clinical application value and broad market prospect.
Owner:HARBIN MEDICAL UNIVERSITY

Application of reagent for inhibiting or detecting Fasn and medicine for preventing and / or treating transplanted vascular remodeling

PendingCN122075518Areduce lesionsrelieve newbornOrganic active ingredientsMicrobiological testing/measurementNeointimaTherapeutic effect
The invention belongs to the technical field of transplanted vascular remodeling diagnosis and treatment, and discloses application of a reagent for inhibiting or detecting Fasn and a medicine for preventing and / or treating transplanted vascular remodeling. Experimental research discovers that a group of novel macrophages capable of self-synthesizing lipid exist in the transplantation blood vessel reconstruction process, and Fasn is remarkably activated, so that intracellular lipid accumulation is caused, and the macrophages are promoted to be converted into foam cells. In-vitro studies show that by inhibiting the activity of the Fasn enzyme or down-regulating the expression of the Fasn enzyme, the transformation of macrophages to foam cells can be obviously inhibited, and the synthesis of lipid in cells can be reduced. Based on the discovery, the nucleic acid medicine constructed by adopting the siRNA is used for treating and / or relieving transplanted vascular remodeling. In-vivo experiments further prove that the nucleic acid medicine can remarkably inhibit intimal hyperplasia of transplanted blood vessels and reduce the neointimal / medial membrane ratio, so that the therapeutic effect is achieved. The method has a good application prospect.
Owner:CENT SOUTH UNIV

Ophthalmic surgical device for sclera

ActiveCN114767377Bcontrol expansionreduce lesionsEye surgerySclera surfaceReoperative surgery
The present invention discloses an ophthalmic surgical device for sclera, comprising a manipulation module, a lifting control module and an arc-shaped shell, wherein the arc-shaped shell has a curvature and length adapted to the shape of the eyeball, and an open cavity is provided on one side of the arc-shaped shell for matching the sclera of the eyeball, wherein the lifting control module is installed in the open cavity, wherein the lifting control module is used to load and apply reinforcing materials and adhesive plasticizers to the sclera of the eyeball, wherein the manipulation module is connected to the lifting control module, and is used to manipulate the lifting control module to lift out of the open cavity to apply the reinforcing materials and adhesive plasticizers to the sclera of the eyeball, and manipulate the lifting control module to reset to the open cavity after the application is completed. The device of the present invention can attach the reinforcing materials to the surface of the posterior sclera through adhesive plasticizers in a minimally invasive, safe and accurately positioned manner, thereby achieving mechanical reinforcement of the posterior sclera, and enhancing constant pressure for the posterior pole or posterior scleral staphyloma.
Owner:SHENZHEN DINGSHI BIOMEDICAL TECH CO LTD

Application of tetrandrine in preparation of medicine for preventing and treating pseudorabies of pig

The application relates to the technical field of animal infectious disease prevention and control, and particularly discloses application of tetrandrine in preparation of a medicine for preventing and treating pseudorabies of pigs. The application can significantly inhibit the replication efficiency of PRV on Vero cells and IPAM cells. When the concentration of the inhibitor is higher than 4 muM, the progeny virus titer and the virus gene transcription level of PRV are significantly reduced compared with those of a control group, and the pathological changes caused by cell infection are effectively relieved, which indicates that the tetrandrine can effectively inhibit the proliferation of PRV and has a potential application prospect.
Owner:YANGTZE UNIVERSITY +1

Mulberry leaf polysaccharide, preparation method and application of mulberry leaf polysaccharide in treatment of AFB1-induced mouse liver injury

The invention relates to the technical field of medicine application, and discloses mulberry leaf polysaccharide, a preparation method and application of the mulberry leaf polysaccharide in treatment of AFB1-induced mouse liver injury. The mulberry leaf polysaccharide can be independently used, and can also be combined with other traditional Chinese medicine extracts to prepare a pharmaceutical composition together. Experimental results show that the liver injury symptom of the mouse treated by the mulberry leaf polysaccharide is obviously improved, the liver index decline trend is relieved, and the liver lesion degree is obviously relieved. Therefore, the mulberry leaf polysaccharide disclosed by the invention can effectively treat liver injury caused by AFB1 and accompanied oxidative stress, and has a wide application prospect in the research field of mulberry leaf polysaccharide antioxidant preparations. The discovery not only provides powerful support for subsequent research and development of the polysaccharide, but also provides a new thought and direction for further optimization and innovation.
Owner:GUANGXI UNIV

A strain of Bacillus licheniformis and its application

ActiveCN119144510Bimprove researchreduce lesionsAntibacterial agentsBacteriaBacillus licheniformisAntagonism
The present invention discloses a strain of Bacillus licheniformis and its application. It belongs to the technical field of probiotics. A strain of Bacillus licheniformis is separated and identified by traditional identification methods and molecular biological methods, and its probiotic performance and safety in animals are evaluated. At the same time, microbiology is combined with pathology, etc., and it is found that oral administration of the bacteria can reduce organ lesions in mice caused by Salmonella, and can produce antagonistic effects on Salmonella in mice. The present invention can not only expand the research on Bacillus, but also provide a reference basis for the future development of probiotic microecological preparations for promoting digestion and growth in animals, antagonizing pathogens, and regulating intestinal microecological environments.
Owner:INNER MONGOLIA AGRICULTURAL UNIVERSITY

Composition comprising mir 145 inhibitor as active ingredient for treatment of myocardial infarction

The present invention relates to a use of a miR-145 inhibitor in preventing aggravation of myocardial infarction or treating myocardial infarction. A miR-145 antagomir reduces ischemic myocardial injury and necrosis upon myocardial infarction and increases the regeneration of myocardial tissues, thereby exhibiting a regenerative therapeutic effect after onset of myocardial infarction. Even when administered alone, the miR-145 antagomir exhibits a similar level of therapeutic effect to that when administered in combination with a miR-124 antagomir, and particularly, brings about a remarkable therapeutic effect at the initial stage (acute phase) within several days after onset of myocardial infarction. Thus, the antagomir can be used for treating myocardial infarction.
Owner:REGEN INNOPHARM INC

Application of magnolol and pharmaceutically acceptable salt thereof in inhibiting bone marrow-derived foam macrophage chronic inflammation after spinal cord injury

The invention discloses application of magnolol and pharmaceutically acceptable salts thereof in inhibiting bone marrow-derived foam macrophage chronic inflammation after spinal cord injury. The invention provides application of magnolol in preparation of drugs for promoting discharge of macrophage lipid, drugs for promoting spinal cord injury repair, drugs for inhibiting lipid accumulation mediated secondary inflammation after spinal cord injury or neuroprotection drugs. The invention further provides a spinal cord injury repairing drug containing magnolol, a drug or reagent for promoting macrophage lipid excretion and a spinal cord inflammation inhibiting drug. According to the application disclosed by the invention, the magnolol is disclosed for the first time by regulating immune cell lipid excretion-inflammatory factor axis, so that the spinal nerve regeneration is obviously promoted, the nerve function is improved, the inflammatory reaction after lipid overload is relieved, and the spinal cord tissue is protected, and an innovative strategy is provided for spinal cord injury treatment. The magnolol synergistically intervenes the secondary neurodegenerative disease after spinal cord injury by improving lipid overload and immune dual pathways, and a brand new direction is provided for SCI treatment.
Owner:THE FIRST PEOPLES HOSPITAL OF NANTONG